Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Isofol Medical Undefined future - DNB

Isofol Medical

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
After the previously announced setback regarding the AGENT study, the Q2 report was largely in line with our expectations. The failed study was disappointing, with the remaining hope that after full data read-out in Q4, a clinical path forward based on sub-groups can be found for arfolitixorin. We see a cash runway until H2 2023, which should give the company some breathing space short-term to determine its long-term strategy. We reiterate our fair value of SEK0–3.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team